Home › Post-COVID Conditions (Long COVID) › NCT04445285

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Male or Female age 18 or older
2. On high flow oxygen =/\> 6 liters nasal cannula (or)
3. On mechanical ventilation
4. Clinical diagnosis of COVID-19 \& positive PCR test (or)
5. Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan

Exclusion Criteria:

1. Known allergy to Pulmozyme
2. Less than 18 years of age
3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
4. Enrollment in another clinical trial receiving investigatory drugs

About the study

This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.

What is being tested

• Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (drug)
• 0.9%sodium chloride (drug)

Sponsor: Jon Simmons · Participants: 44 · Started: Apr 28, 2020

Contact the study team

• Jon D Simmons, M.D. · Phone: 12514459834
• Wendy Blount, RN, MSN · Phone: 2514554566

Official record on ClinicalTrials.gov — NCT04445285

Locations in the U.S.

Conditions

• Post-COVID Conditions (Long COVID)
• COVID-19 and Coronavirus Infections

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.